Eli Lilly stock rose Thursday despite lighter-than-expected sales of its weight-loss and diabetes drugs Zepbound and Mounjaro.

Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...

Eli Lilly stock rose after the drugmaker posted quarterly earnings that beat Wall Street expectations, and issued upbeat 2025 guidance. Fourth-quarter adjusted earnings came in at $5.32 a share, above ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

Thanks to impressive sales growth across multiple therapeutic areas in 2024, Eli Lilly seems to have assuaged investor concerns ... "The scale of this business and the way it's been growing, the ...

(Reuters) - Futures tied to Wall Street's main indexes edged up on Thursday ahead of a wave of corporate earnings, while a ...

Shares in the automaker were lower in premarket trading after the automaker said deep losses in its electric-car business would [weigh on profitability in 2025]( ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

The rest of this week brings more blue-chip earnings, plus one of the most closely watched economic data releases, the monthly jobs report. Here's a rundown: Today Earnings: Results are due premarket ...